A study on calorie restriction found that its health benefits persisted even after researchers statistically controlled for the weight loss, suggesting the restriction itself provides unique advantages.

In studies on older mice, GLP-1 medications produced results similar to the drug Rapamycin, which is known for switching off the mTOR pathway to promote cellular repair.

GLP-1s are hypothesized to promote longevity by mimicking calorie restriction, which flips the body's mTOR pathway from a 'build' state to a 'repair' state.

Longevity influencer Bryan Johnson conducted a microdosing experiment on himself using Tirzepatide, a medication that combines GLP-1 and GIP peptides.

The speaker, a clinician, does not recommend microdosing GLP-1s for healthy patients, comparing it to the similar lack of recommendation for Metformin in the same population.

Bryan Johnson stopped his microdosing experiment after only three weeks because he experienced an unexpected 7% increase in his resting heart rate.

A key risk with GLP-1 medications is that lean muscle can account for 25% to 40% of the total weight lost, which is a major concern for healthy adults.